Therefore, targeting the IL-33/ST2 axis in therapy requires a precise balance of its dual functions, such as developing sST2 antagonists to block pro-inflammatory signals while retaining the activation of membrane-bound ST2 on Tregs, providing a new direction for personalized treatment of RA. Here, IL33 is linked to rheumatoid arthritis.